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2. Introduction   
2.1. Influenza virus classification and structure 
Influenza viruses belong to the family of Orthomyxoviridae and are classified based on 
differences in nucleoprotein (NP) into several genera, including influenza A, B, C, and D 
viruses. Human infections are usually caused either by influenza A (IAVs) or B viruses (IBVs), 
but infections with influenza C viruses has also been reported (Mostafa et al., 2018). While 
IBVs are thought to be restricted to humans and seals, IAVs infect a wide range of species 
(Osterhaus et al., 2000), their most important natural reservoir being aquatic birds (Webster, 
Monto & Braciale 2013; Mostafa et al., 2018). Currently, two seasonal IAVs are circulating in 
humans: H3N2 and H1N1. However, some avian influenza viruses can occasionally infect 
humans with a very high mortality rate (World Health Organisation [WHO], 2018b). 
  The genome of influenza A viruses consists of hair-pin shaped, negative-sense single-
stranded RNA divided into eight segments (Fig. 1). Each segment encodes one or more 
proteins and is coated by multiple viral NPs, as well as a polymerase complex comprised of 
polymerase basic 2 (PB2), polymerase basic 1 (PB1) and polymerase acidic (PA) encoded 
consecutively by first three segments. These ribonucleoproteins (RNPs) are enclosed by a 
matrix protein layer consisting of matrix protein 1 (M1) and matrix protein 2 (M2) which 
functions as an ion channel. The entire particle is also surrounded by host-derived lipid 
bilayer containing two types of viral surface glycoproteins: hemagglutinin (HA) and 
neuraminidase (NA). HA is responsible for binding the host cell receptors and membrane 
fusion, while NA is necessary for the release of the virus. These glycoproteins differ between 
strains and affect their ability to bind cell receptors. In fact, IAVs are classified based on HA 
and NA subtypes. IAVs also encode for several non-structural proteins which have different 
functions in infected host cells, two most important ones being non-structural protein 1 (NS1) 




Figure 1. Structure of IAV. The virion is enveloped by host cell derived lipid bilayer and two 
types of glycoproteins: HA and NA. The nucleocapsid is formed by structural M1 protein and 
ion channels (M2 protein). Inside there are eight viral RNAs (vRNAs) encoding PB2, PB1, PA, 
HA, NP, NA, M1 and M2, NS1 and NEP accordingly. Each segment is coated with NP, PB1, PB2 
and PA, creating viral ribonucleoprotein (vRNP) (Krammer et al., 2018; modified). 
2.2. Viral entry and replication 
In order to understand why influenza outbreaks occur, it is important to know how the 
virus spreads and replicates (Fig. 2). IAV infection is characterized by symptoms such as fever, 
sore throat, cough, runny nose, headaches and fatigue. Although the main target in humans 
is epithelial cells of the respiratory tract, the virus is also able to infect dendritic cells and 
macrophages (Westenius et al., 2014). The modes of transmission for IAVs include water 
droplets, aerosols, direct contact and self-inoculation. Among avian species it can also spread 
via faecal-faecal, faecal-oral or faecal-respiratory tract transmission. Contracting the virus 
directly from water is also possible (Wang and Fish, 2017; Krammer et al., 2018).  
First, the virus binds the host cell via HA, which recognizes receptors ending with sialic 
acid (SA). While human IAVs bind α2,6-linked SA receptors, present in epithelial cells of 
human upper respiratory tract, avian influenza viruses (AIVs) prefer α2,3-linked SA located in 
lower human respiratory tract, as well as in respiratory and intestinal tracts of birds. In 
addition to that, some avian viruses have shown the affinity for both α2,3 and α2,6-linked SA. 
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The fact that avian viruses tend to infect lower respiratory tract in humans may partially 
explain the severity of the infection (van Riel et al., 2013; Chen et al., 2017). 
After receptor binding, the virus is then taken inside of the cell via endocytosis. The 
environment within the endosome is then acidified, which leads to conformational changes 
of HA and opening of M2 ion channel. This allows for influx of H+, acidifying the inside of the 
virion. which leads to the fusion of viral and endosomal membranes and uncoating of the 
virion. Released RNPs are then moved into the nucleus via interactions with importins. Viral 
components are then transcribed by viral RNA polymerase complex. However the cap is added 
using host machinery. Processed transcripts are then translated. New virions can then bud off 
the membrane due to NA activity, which cleaves off SA residues, and can continue infecting 
neighbouring cells (Hsu, 2018; Han, Jeong & Jang; 2019).  
 
Figure 2. Replication of IAV. (1) Entry of the virus via endocytosis. (2) Release of the virus 
from endosome followed by uncoating of the virion. (3) Released RNPs translocate to the 
nucleus. Viral genes are transcribed by viral polymerase. (4) Translation of viral mRNA in the 
cytoplasm using host cell machinery (5) Newly formed viruses bud off the membrane, which 





2.3. Pandemic potential of IAVs 
IAVs are challenging for the immune system because their genome constantly changes. 
This may be partially attributed to the fact that RNA polymerase is more error prone than 
cellular DNA polymerase. In addition to that, IAVs have segmented genomes, which may lead 
to their reassortment (Krammer et al., 2018).  
Antigenic drift, caused by the gradual accumulation of mutations in surface antigens, 
particularly HA, is responsible for seasonal flu epidemics (Fig. 3). Because of these mutations, 
antibodies produced during previous infections can no longer recognize the viral antigens and 
virus is able to successfully replicate (Mostafa et al., 2018). These biannual outbreaks, usually 
during winter in northern and southern hemispheres, are responsible for deaths of estimated 
500 000 people worldwide (Girard et al., 2005). The groups at particular risk of infection are 
pregnant women, children younger than one year old and people over the age of 65 (Krammer 
et al., 2018). Currently circulating seasonal flu viruses are: A/H3N2 and A/H1N1, responsible 
for 73% of flu cases in 2018-2019 in Europe, whereas 27% of infections were caused by IBV 
subtype, mostly attributed to B/Victoria (European Centre for Disease Prevention and 
Control, 2020).  
To limit the scope of these outbreaks, each season a new vaccine is created based on the 
epidemic strains of the previous season, usually consisting of HA and NA proteins. The 
composition of the vaccines is based on the surveillance done by many centres around the 
world, which characterize circulating strains and attempt to predict which ones will be most 
prevalent given year (Krammer et al., 2018).  
Sometimes humans can also be infected by avian strains, but these cases show limited 
human-to-human transmission. The people affected are usually poultry workers. The viruses 
find their way from wild birds into chickens via domesticated ducks and geese. This makes so 
called backyard farming, where different avian species are placed together, particularly prone 
to becoming the source of such outbreaks. The adaptation of avian viruses to human host 
depends on many factors, for example sensitivity of viral polymerase to temperature, since 
avian polymerase tends to work better at lower temperatures than human one (Krammer et 
al., 2018). It was previously shown that introduction of only three mutations to avian H5N1 
subtype is enough for it to establish transmission between ferrets. This is concerning, because 
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ferrets are thought to be good models for studying influenza infections in humans (Herfst et 
al., 2012). 
In addition to epidemics, sometimes a novel virus can emerge, causing a pandemic. This 
may be a result of antigenic shift (Fig. 3). Since influenza viruses are continuously circulating 
among their hosts, two different viruses can infect the same cell and exchange their genetic 
segments. This may grant a virus the ability to cross the species barrier or increase its 
pathogenicity. Zoonotic IAVs possess a particular advantage, since they are entirely new to 
the human immune system and can cause a more severe infection (Widdowson, Bresee & 
Jernigan, 2017). This is additionally emphasized by the fact that all of the pandemics in the 
last century originated from AIVs (Fig. 4) (Kawaoka & Horimoto, 2005; Mostafa et al., 2018).  
 
Figure 3. Difference between antigenic drift and antigenic shift. Antigenic shift may occur 
due to simultaneous infection of two different strains, for example one avian and one human, 
which may lead to the exchange of vRNA segments. The new reassorted virus can acquire new 
traits relatively quickly. Antigenic drift is a result of a slower process, including gradual 
acquisition of mutations in surface receptors (Krammer et al., 2018; modified).  
 
The most deadly of recent pandemic, Spanish flu, was most likely caused by H1N1 
antigenic subtype. It lasted from 1918 to 1919 and it is estimated that 50-100 million people, 
out of around 500 million infected, had died. Additionally, unlike other influenza outbreaks, 
which exhibit highest death toll among the youngest and the oldest, Spanish flu shown 
additional peak of deaths in adults between 20-40 years of age (Kilbourne, 2006; 
Taubenberger, Kash & Morens, 2019).  
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The following pandemic, called Asian flu, occurred in 1957. It was caused by H2N2 
subtype, responsible for 1-2 million deaths worldwide. The virus emerged due to reassortment 
between H1N1 from 1918 with an AIV strain. Around a decade later, in 1968 another global 
outbreak originated in Southeast Asia: Hong Kong flu. The subtype responsible for it was 
H3N2. The virus was an effect of reassortment of H2N2 virus with avian H3-type. Around 
700 000 fatal cases have been reported.  
In 1977 H1N1 strain has reappeared, causing an epidemic, called Russian flu, also referred 
to as an age-restricted pandemic (Kilbourne, 2006). The virus was infecting mostly people 25 
years old or younger, with 50% mortality rate among children. It is thought to be a result of 
lack of immunity against H1 subtype in people born after 1957, when H1N1 was replaced by 
H2N2 virus (Kilbourne, 2006; Mostafa et al., 2018).  
The most recent outbreak, swine flu, classified by some sources as a pseudo-pandemic 
(Kilbourne, 2006), took place in 2009 – 2010. It was caused by H1N1 subtype that emerged due 
to triple reassortment in swine host: it contained several segments from human, swine and 
avian influenza strains. Over 360 000 people have died during that pandemic. However, this 
virus is now circulating as the seasonal H1N1 among humans after adapting to human host, 
and thus it has killed more people after that pandemic season (Kilbourne, 2006; WHO, 2016). 
Both pandemics and seasonal epidemics have great social and economic impact. It is not 
a surprise that there are attempts to predict and prepare for potential new outbreaks. The 
strategy includes, among others, monitoring currently circulating AIVs, which in the future 
may give a rise to a new pandemic strain, as well as attempting to develop pre-pandemic 




Figure 4. Timeline of influenza pandemics and IAVs circulation. Spanish flu was caused by 
H1N1 virus. Then the subtyped was replaced by H2N2 which caused Asian flu. This was 
followed by replacement of H2N2 by H3N2 subtype (Hong Kong flu). Then H3N2 adapted and 
started circulating as seasonal strain. In 1977 H1N1 unexpectedly reappeared causing Russian 
flu. In 2009 a different H1N1 strain emerged due to reassortment between human, avian and 
swine strains (swine flu), replacing the previous one. The new H1N1 subtype seemed to 
undergo antigenic change and is now circulating along with H3N2 as a seasonal flu strain.  
2.4. Avian Influenza Viruses 
AIVs are classified into low pathogenic (LP) and highly pathogenic (HP) strains based 
on their pathogenicity in chickens. Both HP and LP viruses have previously caused human 
infections (Table 1). Although this division does not reflect the severity of the infection in 
humans, HPAIVs tend to be more pathogenic also in humans and cause more acute symptoms 
(Hsu, 2018; Mostafa et al., 2018). 
AIVs, especially those circulating in poultry, have previously caused outbreaks in 
humans. The reason might be the fact that viruses isolated in domesticated birds seem to 
evolve faster than in wild species, possibly due to continuous adaptation to new hosts 
(Mostafa et al., 2018). Several AIV strains are currently being closely examined, since they have 
shown sporadic animal to human transmissions. They do not currently pose a threat, but 




An example of such strain is H5N1 HP virus. The subtype is very diverse: viruses are 
classified into first, second, third and fourth order clades and then into sub-clades. Currently 
only 6 clades are circulating in poultry in Egypt and Southeast Asia (Marinova-Petkova et al., 
2014). Overall, in the span of 15 years (2003–2018) H5N1 has infected 860 people worldwide 
with a 53% mortality rate (WHO, 2018a). It was first shown to cross species barrier in Hong 
Kong in 1997 during an outbreak in poultry when 18 people were infected (Lin et al., 2000; 
Kawaoka & Horimoto, 2005; Parry, 2013). Genetic analysis has shown that several RNA 
segments were acquired from H9N2 virus. The same segments were isolated two years later 
from two patients, which implies they my support poultry-to-human transmission (Lin et al., 
2000).  
The same virus re-emerged in another outbreak in poultry in 2004. The virus spread 
from Vietnam to China, Indonesia, Thailand, and Cambodia (WHO, 2014). It was shown that 
the virus was slowly increasing its ability to infect mammals (Chen et al., 2004). Although the 
possibility of pandemic is currently low, the possible severity of it is the main source of 
concern. 
2.4.2. H7N9 
Another important subtype is H7N9. This LPAIV strain was first isolated in three patients 
in 2013 in eastern China experiencing symptoms of severe pneumonia (Parry, 2013). The virus 
has shown occasional interspecies transmission, as well as few cases of non-sustained human-
to-human transmission (van Riel et al., 2013; Peiris et al., 2016; Mostafa et al., 2018). Unlike 
other AIV strains, H7N9 is able to attach to both lower and most importantly, upper 
respiratory tract (van Riel et al., 2013). In addition to that, an emerging HPAIV H7N9 strain 
was discovered four years later. The acquired mutations increased the activity of viral 
polymerase, and thus replication (Yamayoshi et al., 2018). However, it is not clear if these 
mutations significantly affect the virulence (Mostafa et al., 2018). 
2.4.3. H7N7 
H7N7 HPAIV has been previously reported to infect people, with the most human cases 
occurring during an outbreak in poultry in 2003 in Netherlands. The number of infections was 
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higher than expected, reaching 89 people. Most people experienced only mild symptoms, but 
one fatal case was reported (Van Kolfschooten, 2003; Koopmans et al., 2004). In 2013 a LPAIV 
H7N7 virus containing genes from H9N2 subtype was discovered in chickens in China. There 
were no human infections, but the virus was experimentally shown to infect mammals (Lam 
et al., 2013).  
2.4.4. H9N2 
H9N2 LPAIV, despite usually not causing any clinical symptoms, has been closely 
monitored. The strain may pose a risk due to its relatively high incidence rate of zoonotic 
transmission and its prevalence among poultry in Europe and Asia (Schrauwen and Fouchier, 
2014). Additionally, the presence of antibodies among poultry workers in affected region 
suggests that most cases are quite mild and often go undetected (Li et al., 2017).  
All previously discussed strains (H5N1, H7N9, H7N7) have acquired some of the genes 
from H9N2. It is thought they play a role in an increased transmission efficacy between species 
(Mostafa et al., 2018). Moreover, H9N2 can also infect pigs, which are said to be an 
intermediate between avian and human infections (Sun et al., 2020). 
Table 1. Chosen AIVs showing pandemic potential 
Subtype Summary 
H5N1 53% mortality rate, severe symptoms 
H7N9 38% mortality rate, severe symptoms, multiple human outbreaks 
H7N7 mild symptoms, 1 fatal case, few human outbreaks 
H9N2 low mortality rate, high risk of zoonotic transmission 
 
Monitoring poultry-to-human infections has shown that AIVs are constantly evolving. 
Mixing genes from different strains may lead to increased pathogenicity and eventually more 
effective spreading potential. Understanding which factors contribute to infection, replication 
and interspecies transmission is important for better pandemic preparedness. 
2.5. Immune antiviral response 
In order to prevent the entry and replication of a pathogen, there are two lines of 
defence: innate immunity and adaptive immunity. Innate immunity is unspecific, as it 
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responds to elements shared by many pathogens, such as double-stranded DNA or 
components of a bacterial wall. It consists of physical barriers, such as skin and mucus, as well 
as phagocytosis, cytokines and other proteins. Adaptive immunity is more specific and can be 
divided into cell-mediated immunity and antibody-mediated immunity. Both innate and 
adaptive immunity have a role in supressing viral infections (Krammer et al., 2018). 
2.5.1. RIG-I pathway 
When pathogen gets through physical barriers, first step leading to the immune 
response is detection of its entry. This can happen through pattern recognition receptors 
(PRRs), which recognize pathogen associated molecular patterns (PAMPs). PPRs can be either 
membrane bound or cytoplasmic. The most important pathway in influenza virus detection 
is retinoic acid-inducible gene I (RIG-I) pathway (Fig. 5), which leads to the production of 
interferons (IFNs) (Pichlmair et al., 2006).  
Signalling begins when RIG-I is activated by binding PAMPs, such 5’ triphosphorylated 
end of double-stranded RNA (dsRNA). The signal is then transduced via adaptor protein 
MAVS to inhibitor of nuclear factor kappa B (IκB) kinase α (IKKα), IKKβ and IKKγ complex, 
which can phosphorylate the IκB and one of the subunits of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) transcription factor. This leads to disassociation of IκB 
from NF-κB and its degradation in a proteasome. Released and phosphorylated NF-κB can 
then translocate to the nucleus via importins and bind NF-κB binding site in the IFN 
promoter. Another kinase complex that is activated by MAVS, IKKε and TANK-binding kinase 
1 (TBK1), can phosphorylate interferon regulatory factor 3 (IRF3) in order for it to create a 
homodimer and bind interferon-sensitive response elements (ISRE) within IFN gene 
promoter. IRF3, which is expressed constitutively, can also heterodimerize with IRF7, present 
in the cell in a low amount but expressed strongly in response to stimulation by IFNs, thus 
creating positive feedback. All of the above virus-induced signalling pathways activate IFN 






Figure 5. RIG-I pathway. Viral RNA is bound by RIG-I protein which triggers signalling 
cascade via MAVS and the above kinases (IKKα, IKKβ, IKKγ, IKKε and TBK1) leading to 
phosphorylation of several transcription factors. These factors then translocate to the nucleus 
and bind regulatory elements within IFN gene promoter (Jiang et al., 2015; modified). 
2.5.2. Interferon functions 
Interferons are a group of cytokines with versatile functions in overcoming an infection. 
They can be divided into three classes based on their receptors: type I, type II and type III. 
Type I interferons include several IFN-α subtypes, IFN-β, IFN-ε, IFN-κ and IFN-ω. Type II 
interferon only consist of IFN-γ and type III IFN of IFN-λ1-4. Type I and III are produced by 
epithelial cells, macrophages and dendritic cells upon the infection in order to inhibit viral 
replication. Then the release of inflammatory cytokines attracts more immune cells, such as 
natural killer cells. Interferons can greatly limit the infection, but excessive cytokine 
production may lead to lung damage (Krammer et al., 2018). Of type I and type III IFNs, both 
IFN-β and IFN-λ1 promoters contain IRF and NF-κB binding sites (Österlund et al., 2007; 
Pietilä et al., 2007). Type II IFNs differ from type I and III IFNs, since they are mainly produced 
by immune cells. In addition to that, they are stimulated by other IFNs and interleukins, only 




2.5.3. Interferon signalling 
Despite might having evolved separately, IFNs use a similar signalling pathway (Fig. 6). 
The binding of these IFNs to their own type of receptors, IFNAR for type I and IFNLR for type 
III IFNs, leads to the phosphorylation of the janus kinase (JAK) -mediated activation of signal 
transducer and activator of transcription 1 and 2 (STAT1/2) proteins, and this allows IRF9 
binding. The formed interferon stimulated gene factor 3 complex then translocates to the 
nucleus and binds to ISRE elements triggering the transcription of interferon stimulate genes 
(ISGs) (Platanias, 2005). 
Upregulated expression of IFNs regulates the state of infected and neighbouring cells via 
autocrine and paracrine signalling. It is manifested mainly by modulating immune response, 
cell growth and metabolism (Wang and Fish, 2017). 
It has been shown, that different IAVs differ significantly when it comes to inducing IFN-
β expression (Han, Jeong & Jang, 2019). H7N9 strain can avoid host-cell recognition very well 
and IFN induction is lower than in cells with seasonal flu virus infection. On the contrary, 
H5N1 virus causes so called cytokine storm, yet it is able to replicate very effectively (Arilahti 
et al., 2014).  
 
Figure 6. Interferon signalling pathway and ISGs expression. Upon IFN binding both IFN type 
I and III trigger signalling cascade that leads to the phosphorylation of STAT1/2 proteins. A 
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heterotrimer with IRF9 is formed and translocated to nucleus, where it binds to ISRE within 
ISGs promoters. The binding allows for expression of various ISGs, such as OAS, PKR, IRF7 
and MxA, which creates antiviral state in infected and neighbouring cells. IRF7 also 
additionally upregulates IFN genes expression and acts as a positive regulator of transcription 
(Julkunen et al., 2001; modified). 
2.5.4. Interferon stimulated genes 
An important role of IFNs during viral infection is increasing the expression of various 
ISGs, such as myxovirus resistance gene A (MxA), IRF7, 2'-5' oligo (A) synthetase (OAS) and 
RNA-dependent protein kinase (PKR), which further induce antiviral state in infected or 
neighbouring cells.  
MxA is an important protein in influenza infection in humans is. It is a cytosolic GTPase 
induced only by IFNs and STAT signalling. Infection of the virus alone is not enough to 
activate its expression. Its main role is inhibition of viral protein synthesis (Pavlovic, Haller & 
Staeheli, 1992; Haller & Kochs, 2011). In addition to that, MxA modified to localize in nucleus 
was shown to inhibit viral transcription via interactions with NP (Turan et al., 2004). The 
sensitivity to its activity differs between IAV strains: avian strains seem to be more affected 
than human viruses (Haller & Kochs, 2011). 
IRF7 is a major regulator of IFN gene expression. Small amounts of IRF7 are normally 
present in cytoplasm in an inactive form. However, in early stages of the infection PRRs 
phosphorylate IRF7, and thus activating it. This allows for its translocation to nucleus and 
activation of IFN promoter. IFNs in turn increase the expression of IRF7, creating a positive 
feedback loop (Drappier & Michiels, 2015).  
OAS is a protein activated by dsRNA, responsible for synthesis of short 2’5’ 
oligonucleotides that act as activator for RNase L. RNase L dimerized and cleaves both viral 
and cellular single-stranded RNA. The former directly prohibits replication of viral genome, 
the latter leads to apoptosis of infected cell, which limits the spread of the virus (Drappier & 
Michiels, 2015). In addition to that, cleaved segments of RNA may further activate RIG-I 
(Nogales et al., 2018). 
PKR is constitutively expressed in cells, but can be further expressed and activated in 
two ways: through binding of dsRNA or by protein activator of the interferon-induced PKR 
(PACT). PKR is then able to phosphorylate cellular proteins, including eukaryotic initiation 
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factor 2, which inhibits protein synthesis of both cellular and viral proteins (Li et al., 2006; 
Klemm et al., 2018; Nogales et al., 2018).  
Although the ISGs described above are the most relevant regarding influenza infection, 
there are many other including ISG15, which acts through ISGylation of proteins relevant for 
viral replication (Perng & Lenschow, 2018), or interferon induced transmembrane protein 3, 
which prohibits fusion of host and viral membranes at the first step of the infection (Fig. 2) 
(Nogales et al., 2018).  
RIG-I pathway, IFN expression and signalling, as well as ISGs expression are the most 
important factors leading to an effective antiviral immune response. However, those 
mechanisms are not always enough to prohibit the spread of the virus. 
2.6. Viral immune evasion 
In order to replicate successfully, viruses had to evolve mechanisms to overcome host 
defences. They include, among others, regulation of IFNs and ISGs expression. During IAV 
infection, these functions are mostly mediated by NS1 protein (Hale et al.,2008). 
2.6.1. Structure and synthesis of NS1 
NS1 is a protein encoded by the eighth, shortest RNA segment of the influenza virus, 
along with NEP. Both NEP and NS1 transcripts are a result of splicing. Their sequences are not 
independent: they share ~56 nucleotides at the 5’end of the transcript (Lamb & Lai, 1980). NS1 
is expressed at high level in infected cells. Its synthesis seems to be partially autoregulated: it 
has been shown that NS1 can inhibit the splicing of the mRNA leading to the downregulation 
of NEP expression. This explains the considerably lower amount of NEP as compared to the 
levels of NS1 found in infected cells (Garaigorta & Ortin, 2007). Even though it is considered 
to be a non-structural protein, it is found in small amounts in the virion (Hutchinson et al., 
2014). 
NS1 has a molecular weight of around 26 kDa and consists of 215-237 amino acids (Han, 
Jeong & Jang, 2019). It comprises the RNA-binding domain (RBD) capable of binding RNA 
independently of the sequence, the linker domain (LD), the effector domain (ED) responsible 
for interactions with host cell proteins and stabilizing RBD and the C-terminal tail (CTT). A 
nuclear localization signal (NLS) is encoded within RBS. Most IAVs also contain second NLS 
within CTT and nuclear export signal (NES) within the effector domain (Fig. 7). NS1 protein 
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is present in the cell as a homodimer. Both RBD and ED contribute to the dimerization (Hale 
et al., 2008).  
NS1 can be found mainly in the nucleus, but it is still present in a significant amount in 
cytoplasm, especially in later stages of the infection. Its localization in the cytoplasm may be 
mediated by three different mechanism: initial accumulation of transcripts in the cytoplasm 
along with masking of NLS, unmasking of NES or by competition between NLS and NES (Hale 
et al., 2008). The distribution of NS1 between cytoplasm and nucleus may be a strain-specific 
trait (Wang and Fish, 2017).  
There is variation in the amino-acid chains of the protein between different IAV strains. 
For example, H3N2 shares only around 67% of the sequence of NS1 of H5N1. Differences in 
the effector domain are said to be responsible for changes in the functionality of NS1 (Han, 
Jeong & Jang, 2019). Another factors adding to variations between strains is post-translational 
modifications of NS1, such as phosphorylation (Hale et al., 2008). 
NS1 is a multifunctional protein responsible, among others, for interfering the host 
antiviral response and determining viral pathogenicity (Fig. 8). 
 
Figure. 7 Schematic structure of NS1. NS1 protein consists of ~237 amino acids. It comprises 
RNA-binding domain (RBD), linker domain (LD), effector domain (ED) and C-terminal 
domain (CTT). Most of the strains contain two nuclear localization signal (NLS) sequences 
and one nuclear export signal (NES) sequence (Nogales et al., 2018; modified). 
2.6.2. Inhibition of interferon gene expression 
The main role of NS1 that enables escaping immune evasion is avoiding detection and 
thus inhibition of an interferon response. This can be done at various steps of the RIG-I 
pathway. It was shown that NS1 can compete with RIG-I for 5’-triphosphate vRNA binding. 
RIG-I pathway induction may also be limited by binding of NS1 to tripartite motif-containing 
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protein 25 (TRIM25), which inhibits ubiquitination, and thus the activation of RIG-I (Gack et 
al., 2009). Another mechanism of NS1 in suppressing IFN signalling includes preventing 
transcription factors from entering the nucleus, either by binding the IκB and protecting it 
from degradation, or by blocking the phosphorylation of IRF3 (Klemm et al., 2018).  
In addition to that, NS1 can inhibit IFN signalling via inhibition of host mRNA 
production and processing. It is achieved via cleavage and polyadenylation specificity factor 
30 (CPSF30) and poly(A)-binding protein II (PAB II) binding, which take part in adding 
poly(A) tail to transcripts (Keller et al., 1991; Hsu, 2018).  
2.6.3. Inhibition of ISGs 
Another way NS1 can mitigate the result of IFN expression is interfering with ISGs. 
Inhibition of viral detection via RIG-I and STAT-signalling alone indirectly affects MxA and 
IFR7 activity, since these proteins heavily rely on PPRs and IFNs. In case of ISGs such as OAS 
or PKR, which are activated by binding of vRNAs, NS1 prevents their activation via 
sequestration of dsRNA though its RBD. In addition to that, PKR can also be inhibited directly 
through NS1 binding (Li et al., 2006; Nogales et al., 2018). 
 
Figure 8. Summary of chosen functions of NS1 protein. NS1 can promote viral replication via 
several mechanisms. They include suppression of IFN genes expression through competing 
for vRNAs with RIG-I and interactions with TRIM25, as well as inhibition of antiviral state 
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through interference with ISGs and restricting transcription through CPSF30 and PAB II 
binding (Han, Jeong & Jang, 2019; modified) 
2.6.4. Other NS1 functions 
NS1 can benefit the virus in many other ways, one of them being the activation of 
phosphoinositide 3-kinase (Pi3K) pathway, which supresses apoptosis before replication is 
complete. Additionally, Pi3K can act through IRF3 as an alternative path for IFNs induction. 
NS1 is also capable of DExD-box helicase 21 binding, which when unbound prohibits it from 
interfering with assembly of viral polymerase complex. NS1 has also been shown to assist in 
the preferential translation of viral mRNAs via the recruitment of eukaryotic translation 
initiation factor 4GI to their 5’UTR (Klemm et al., 2018; Han, Jeong & Jang, 2019).  
The plurality of mechanisms through which NS1 can modulate cell’s immune response 
against infection highlights its importance in determining efficiency of viral replication and 
pathogenicity.  
2.6.5. NS1 and efforts to control influenza outbreaks 
Given the importance of NS1 in viral pathogenicity, the protein seems to be an obvious 
target for the creation of live attenuated vaccines. There have been several studies using 
viruses lacking NS1 gene as potential vaccines. An example can be a vaccine against H1N1 virus 
that is currently in phase I clinical trials. It was shown that IgA antibodies were able to 
neutralize not only H1N1 subtype, but also were effective for H5N1 and H3N2 viruses (Wacheck 
et al., 2010; Morokutti, Muster & Ferko, 2014) Another vaccine which is in phase I/II clinical 
trial aimed at H1N1, H3N2 and one of IBV seasonal strains has been shown to be safe for use 
(Mössler et al., 2013). 
There are also vaccines developed for chickens, in order to limit the prevalence of IAVs 
in poultry and thus decreasing the risk of a pandemic arising from an avian strain. An example 
is a vaccine against H9N2 virus with a truncated NS1 gene. This vaccine has shown greater 
immunization when compared to an inactivated one (Chen et al., 2017). 
Currently used antivirals are targeting either M2 ion channel or NA. There are usually 
used only for patients experiencing severe symptoms, but in case of the pandemic they would 
be crucial to manage the outbreak (Krammer et al., 2018). However, there are no alternatives 
in case of resistance towards the treatment. This creates a need for finding new drug targets. 
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NS1 is one of the proteins of interest due to its key role in successful viral replication. The 
approaches include designing short interfering RNAs, anti-NS1 antibodies and other small 
molecules targeting various NS1 interactions, particularly RNA binding. Unfortunately, these 
studies had very little success (Krammer et al., 2018; Rosário-Ferreira et al., 2020). 
3. Aims 
The aim of this Master’s project was to assess the changes in activation of type I and III 
interferon gene promoters in presence of NS1 proteins originating from five different avian 
influenza strains and one seasonal influenza strain.  
4. Materials and methods 
4.1. Cell cultures and virus infection 
Human embryonic kidney epithelial cell line (HEK293) was maintained in (EAGLE-
MEM) (Sigma-Aldrich) supplemented with antibiotics (penicillin and streptomycin), 
L-glutamine, HEPES and 10% fetal bovine serum and split every third day or when the 
confluency was approx. 70%. For transfection experiments cells were plated in 24-well plates 
using medium supplemented with only 2% fetal bovine serum around 15-20h before the 
transfection. Preferred confluency for the transfection was 80-90%. The parameters of the 
incubator were 5% carbon dioxide concentration with humidity and temperature of 37°C. 
4.2. Plasmids 
For IFN promoter-reporter constructs IFN-β and IFN-λ1 promoter sequences were 
cloned into the pGL3-basic vector expressing the firefly luciferase (FFluc) (Promega) as 
described previously (Österlund et al., 2007). IFN-β promoter sequence was inserted into 
NheI restriction sites and IFN-λ1 between MluI and XhoI (Fig. 9a). Renilla-luc (Rluc) plasmid 
was creating analogically.  
 Constructs containing different influenza virus NS1 genes with a N-terminal flag-tag 
sequence were cloned in the pcDNA3.1 plasmid (Julkunen et al., 2001). The NS1 gene was 
driven by a T7 constitutive promoter (Fig. 9b). The sequences came from seasonal flu IAV 
strains: A/Beijing/353/1989 (H3N2), and 5 different AIV strains: A/HK/156/1997 (H5N1/97), 
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A/VN/1203/2004 (H5N1/04), A/NL/219/2003 (H7N7), A/Anhui/1/2013 (H7N9) and 
A/HK/1073/1999 (H9N2). 
PmKate2-NS1 H5N1 A/HK/156/97 was constructed by cloning the NS1 gene sequence 
from H5N1 A/HK/156/97 fused to the mKate2 N-terminus (Evrogen) into BamH1 site under a 
CMV promoter (Fig. 9c).  
 
Figure 9. Simplified structure of plasmids used in the experiments. (A) Luciferase expression 
plasmid: IFN-β or IFN-λ1 promoter is driving a luciferase gene. (B) NS1 expression plasmid: 
flag-tagged NS1 gene driven by a T7 constitutive promoter. (C) NS1-mKate fluorescence fusion 
protein expression plasmid run by CMV constitutive promoter.  
4.3. Transfection and IFN promoter induction 
For the experiment cells were co-transfected with FFluc plasmids (100 ng/well), as well 
as a plasmid containing a gradient of NS1 (20 ng – 100 ng – 500 ng) from the 6 previously 
described influenza strains using TransIT®-2020 Transfection Reagent (Mirus). The amount 
of DNA was made up to 500 ng with an empty vector (pcDNA). Rluc plasmid (3 ng/well) was 
used as a control of transfection efficiency. 
For live-cell imaging during experiment optimization flag-tagged NS1 expression 
plasmids were replaced with pmKate2-NS1 H5N1/97. 
After 4 hours incubation, the cells were infected with Sendai virus (SV) (strain Cantell, 
originates from National Public Health Institute, Finland, the former THL and was cultured 
in embryonated chicken eggs and then stored at -70 °C) (Ronni et al., 1995). The virus was 
chosen because it is as strong inducer of IFNs. It also has less interfering properties than 
influenza viruses, which would produce additional NS1 during the infection. SV was diluted 
1:100 in EAGLE-MEM. In order to analyse the IFN promoter-driven luciferase and the protein 
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expression of NS1 the cells were lysed in 1x passive lysis buffer (Promega) after 24 h incubation. 
Collected lysate was then separated for a luciferase assay and western blotting. 
4.4. Protein expression analysis 
4.4.1. Luciferase assay 
A luciferase assay (Dual-Luciferase® Reporter Assay System, Promega) was performed to 
measure activation of interferon promoter using Victor multiplate reader (Wallac). The values 
were used to calculate fold induction of IFN gene promoter activation: FFluc counts per 
second (CPS) were divided by Rluc CPS. Negative control (ctrl -), the cell samples that were 
transfected with pcDNA and not infected with SV, was assigned the value 1. The fold induction 
for the rest of the samples was calculated in regard to that value. Positive control (ctrl +) 
comprised the cells that were transfected with pcDNA and infected with SV. 
4.4.2. Western blotting 
The cell lysate in passive lysis buffer (Promega) was mixed with 4x Laemmli buffer and 
boiled for denaturing the proteins before separated in 12% SDS-PAGE gel. After the 
electrophoresis proteins were transferred to Hybond-P polyvinylidene difuoride (PVDF) 
membranes (Amersham Biosciences). The membranes were blocked with 5% milk protein in 
PBS. The staining was done with primary anti-FLAG (Sigma F1804 M2, 1:1000 mouse dissolved 
in 5% BSA) and anti-GAPDH (Cell Signalling Tech, #2118 rabbit) antibodies at room 
temperature for 1 h. Secondary antibody staining was done with anti-mouse (for anti-FLAG 
staining) and anti-rabbit (for anti-GAPDH staining) HRP-conjugated antibodies (Dako) at 
room temperature for 1 h. Protein bands were visualized on HyperMax films using Pierce ECL 
plus system (Thermo Fisher Scientific).  
5. Results 
5.1. Optimization of the experiment 
In order to assure the reliability of the data, several elements needed to be optimized. First, 
the appropriate amount of NS1-containing plasmid needed to be determined, so that the NS1 
protein gradient is visible in blots and that the expression levels between different influenza 
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strains are relatively constant (Table 2). The gradient chosen for the experiment was 
20 ng – 100 ng – 500 ng, since it created a visible differences between plasmids amounts.  
Table 2. Optimization of NS1 expression plasmid amount 
Gradient of NS1 expression plasmid Result 
50 ng – 200 ng – 500 ng 
200 ng and 500 ng are too similar, difficult to 
distinguish 
20 ng - 100 ng - 500 ng 
20 ng band not visible; clear gradient between 
200 ng and 500 ng 
Secondly, the amount of Rluc-expressing plasmid, where Rluc is expressed at higher levels 
than IFN promoter-induced FFluc because it is driven by constantly high-active SV40 
promoter, needed to be selected so that the background is not too strong regarding the IFN 
promoter-induced FFluc and the differences in IFN induction are visible. The amount chosen 
was 3 ng for Rluc and 100 ng for FFluc (Table 3).  
Table 3. Optimization of Rluc- expressing plasmid amount 
Rluc- expression plasmid Result 
10 ng – 100 ng background too high, low induction fold 
3 ng – 100 ng lower background, higher induction fold 
Lastly, the incubation time between the transfection and infection, as well as the 
dilution of the virus needed to be established. It was important to balance these factors in 
order to get sufficient transfection efficiency and expression of NS1 molecules, avoid killing 
too many cells, but at the same time to get detectable virus-induced IFN response. This was 
determined by live-cell imaging of mKate expression (Table 4). Optimal results were achieved 
using 1:100 dilution for the virus and 24 h incubation before the infection. However, when a 
new batch of cells was provided, cells with lower passage history displayed a satisfactory NS1 
expression levels already after 4 h incubation. It is possible that initially 4 h incubation 
between transfection and infection was not enough to see mKate protein expression, given 
that transfection alone is already stressful for the cells. Viral infection may have caused too 
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many cells to die. Fresh batch of cells seemed to have a better vitality so 24 h incubation before 
the infection was not necessary. 
 
Table 3. Assay to determine optimal parameters for IFN promoter induction 
  Amount of time 
  4 h 24 h 
Sufficient dilution 
of SV 
1:100 mKate2-NS1 expressed 
in few cells 
mKate2-NS1 expressed 
in most cells 
1:500 no IFN activation no IFN activation 
 
Additionally, in order to reduce variability between samples and replicates, a mix of 
pcDNA and NS1 plasmids for each strain was premade. Analogical mix was created for renilla 
and IFN promoter plasmids. 
 
5.2. Expression of NS1 protein 
To ensure the NS1 protein gradient is visible and that the expression level is comparable 
between strains, western blotting was performed (Fig. 10). The anti-FLAG antibodies were 
chosen, since anti-NS1 antibodies display different affinity between strains. This was followed 
with anti-GAPDH staining to control the equal loading between the wells.  
With the selected plasmid concentrations most of the NS1 clones were expressed at the 
same efficiency. However, the NS1 clones originated from the H5N1/04 and H7N7 strains 
tended to be expressed at lower efficiency most of the times. The differences were not caused 
by incorrect loading, since GAPDH was expressed equally in all the wells. Regardless of the 




Figure 10 Expression of antiviral NS1 protein of H5N1/04 , H7N9, H3N2, H7N7, H9N2 and 
H5N1/97 in HEK293 cells. Cells were transfected with (A) IFN-β and (B) IFN-λ1 FFluc reporter 
plasmids along with a gradient (20 ng – 100 ng – 500 ng) of NS1 expression plasmids from 
chosen IAV strains. After 4 h incubation all samples were infected with SV. Cell lysates were 
collected 24 h after infection, analysed by Western blotting using anti-FLAG antibodies. 
GAPDH protein expression was analysed to control equal loading of the samples. 
A representative experiment out of 8 is shown. 
5.3. Sendai-induced activation of IFN-β and IFN-λ1 promoters in the presence of 
different IAVs NS1 proteins 
In order to stimulate IFN promoter activation, the cells were infected with SV. Following 
this, a luciferase assay was performed to assess the efficiency of different NS1 proteins in 
supressing IFN activation (Fig. 11). 
The maximum observed fold induction of IFN-β promoter reached over 8-fold (Fig. 11a). 
It was suppressed the most by H3N2 (seasonal flu) NS1, closely followed by H7N9, H5N1/04 
and H5N1/97. Regarding the luciferase results between 100 ng and 500 ng samples for H7N9, 
H5N1/04 and H5N1/97 strains, there is not a clear gradient in suppression of IFN activation 
although the expression of NS1 proteins in western blots show the difference between the 
amount of plasmids used (Fig. 10). However, the difference in IFN activation between these 
samples is minor and may imply that the strongest effect of these NS1 proteins are achieved 
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already in the 100 ng sample, so increasing its amount does not affect IFN promoter activation 
further. The lowest suppression in IFN-β activation was seen respectively with H7N7 and 
H9N2 strains. The gradient between all samples was visible and reflected protein expression 
seen in western blots.  
The IFN-λ1 promoter showed greater induction by SV, which reached 24-fold (Fig. 11b). 
In all of the strains, IFN-λ1 activation corresponded to the NS1 gradient. As in the case of IFN-
β, H3N2 was the most efficient in suppressing IFN-λ1 promoter. Very strong IFN promoter 
suppression was also observed for NS1 of H7N9 and H5N1/97. NS1 of H7N7 was not as efficient 
at suppressing IFN-λ1 promoter. IFN-λ1 activation in the presence of NS1 from H9N2 was 
rather high, ranging between a 9,5- and 5,4-fold change. The lowest suppression of IFN-λ1 
promoter was observed for H5N1/04. However, this results for may be caused by the fact, that 




Figure 11. Activation of IFN-β (A) and IFN-λ1 (B) promoter in SV-infected HEK293 cells. 
Before infection the cells were transfected with a gradient of NS1 protein expression plasmid 
(20 ng – 100 ng – 500 ng) from several IAV strains: H5N1/04, H7N9, H3N2, H7N7, H9N2 and 
H5N1/97. Ctrl - samples were transfected only with Lluc and Rluc plasmids and with an empty 
plasmid without NS1 gene. Ctrl + samples were additionally infected with SV. Cells were 
collected after 24 h incubation and lysed, and the luminescence was measured. Fold induction 
was calculated based on CPS values + standard deviation. The graphs show an average fold 





NS1 plays an important role, not only in the regulation of type I and III IFNs induction 
and inhibition of ISGs, but also in various other processes influencing viral replication and 
pathogenicity. It has been shown that changes in NS1 sequence that affect IFN gene expression 
during the infection have an effect on virulence, host range and tissue tropism of the strain 
(Ma et al., 2010; Kanrai et al., 2016). For example, D92E substitution in NS1 of H5N1 viruses 
resulted in more efficient replication in chicken and mice (Seo et al., 2002).  
H3N2 suppressed the promoter activation the most for both IFN-β and IFN-λ1 and 
usually the infection manifests itself rather mildly. Similar results were obtained by Hsu (2011), 
where H3N2 has suppressed immune response with greater efficiency than H5N1 subtype in 
human lung cells. The reason for the efficiency of its NS1 in IFN promoter suppression may 
be the fact that the virus is already adapted to infecting humans and evading the immune 
response. There are studies which imply that as H1N1 circulates in humans, it slowly regains 
its ability to supress IFN expression, also suggests that adaptation may be the reason for the 
high IFN suppression (Clark et al., 2017). Even though the role of NS1 in adaptation to other 
species has not been established yet, Basler and co-workers has shown that a mouse strain of 
IAV transformed to express human NS1 of H1N1 Spanish flu virus was not able to replicate in 
mice (Basler et al., 2001). On the other hand, mouse IAV strain expressing human NS1 was 
able to replicate more efficiently in human lung cells then the wild type (Geiss et al., 2002). 
Second highest IFN-λ1 and IFN-β promoter suppression was observed for NS1 from 
H7N9. This aligns with the results reported by Arilahti (2014), where H7N9 infection was 
characterized with lower IFN induction in monocyte-derived dendritic cells than seasonal 
H3N2 virus, but replicated as well as H5N1 strain. Similar observations were made by Josset et 
al., where H7N9 shown reduced proinflammatory cytokine production when compared to 
H3N2 (Josset et al.,2014). This may suggest H7N9 has a higher potential for adaptation to 
human host.  
Even though in this study NS1 of H7N9 shown very high IFN promoter suppression, it 
was not higher than in presence of NS1 of H3N2 strain. This may suggest that NS1 is not alone 
responsible for the difference in IFN induction, other factors are involved in the regulation 
instead. An example may be PA-X protein, which, like NS1, can also influence IFNs 
production, but uses a different mechanism of action. There are also multiple other 
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mechanisms in addition to IFN promoter suppression. One of them is inhibition of pre-mRNA 
processing, including IFN mRNAs. (Nogales et al., 2018).  
Out of the studied strains, H5N1/04 and H5N1/97, which cause the most severe 
symptoms and high death rates in humans, seemed to be efficient at suppressing IFN-β 
promoter activation. These results did not exactly reflect what was shown by Arilahti (2014), 
where H5N1/04 infection generated a cytokine storm. H5N1 was previously shown to induce 
stronger IFN-β and IFN-λ1 response through higher activation of IRF3 compared to seasonal 
H1N1 virus (Hui, 2009). However, it should be noted that during a viral infection, initially, the 
NS1 is not present in marked amounts in the cell, it is produced when viral genes are 
expressed. In this experiment the IFN promoter suppression may have taken place earlier than 
it would occur during viral infection. In addition to that, only IFN promoter activation, not 
IFN expression, was measured.  
When it comes to IFN-λ1 promoter, H5N1/04 was the least sufficient in suppression of 
IFN promoter activation. Previous H5N1 virus outbreaks has demonstrated that excessive 
cytokine production may lead to lung damage, hence severity of the infection and high 
mortality rates (Kuiken et al., 2012; Zeng et al., 2012). Surprisingly, efficiency in IFN-λ1 
promoter suppression of H5N1/97 resembled the results obtained for NS1 of H9N2. Studies 
conducted by Seo and colleagues has suggested that H5N1/97 are resistant to the effects of 
IFNs: transformation of human IAV strain with NS1 of H5N1/97 was able to replicate in 
presence of IFNs, unlike the human strain, which replication was inhibited. (Seo et al., 2002). 
Other research has also shown that H5N1/97 infection heavily induces proinflammatory 
cytokines and reduces production of anti-inflammatory cytokines. The imbalance between 
those two was proposed to be responsible for the severity of symptoms during the infection 
(Lipatov et al., 2005).  
H7N7 and H9N2 are associated with mild or lack of symptoms and their NS1 shown quite 
low efficiency at suppressing both IFN-β and IFN-λ1. In Westenius (2014) study, H9N2 virus 
infection was also shown to induce strong IFN genes expression. However, the virus was very 
sensitive to the effects of type I IFNs, hence explaining the relatively mild course of infection. 
H7N7 viruses lacking NS1 are attenuated in chickens. However, the main role of NS1 seems to 
be inhibition of antiviral state and not necessarily supressing IFN genes expression, since the 
level of IFNs without functioning NS1 was not increased compared than in wild type (Penski 
et al., 2011). 
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This study has given some insight into how efficiently potentially pandemic AIV strains 
can inhibit IFN response, and thus prolong the infection. Even though a definitive correlation 
between NS1 of various strains and the symptoms caused by them cannot be drawn, these 
results may be a base for further studies at a deeper mechanistical level, for example which 
steps of RIG-I pathway are key for suppression of IFN promoter activation by chosen AIVs. 
The results of the thesis may also be further validated by assessing the expression level of IFN 
mRNA with qPCR or produced IFN proteins with ELISA test.  
Currently, more research is needed to fully determine the relevance of NS1-dependent 
suppression of IFN promoter activation in pathogenesis of the virus. A better understanding 
of factors influencing host immune response could improve clinician’s ability to control it and 
increase the survival of the patient.  
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